Analysts' Perspective: Barclays (BCS), Clovis Oncology (CLVS), Splunk (SPLK), Puma Biotechnology (PBYI)
Analysts at HSBC Securities upgraded Barclays PLC (NYSE:BCS) shares from a Hold to a Buy rating
Barclays is a global financial services holding company. It is engaged in retail banking, credit cards, wholesale banking, investment banking, wealth management and investment management services.
Brokerage firm Stifel reiterated a Buy rating and boosted its price target from $30.00 to $45.00 on shares of Clovis Oncology, Inc. (Nasdaq:CLVS),while analysts at Credit Suisse upgraded the company's stock from Neutral to Outperform
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets.
Equities researchers at Mizuho initiated coverage on Splunk Inc. (Nasdaq:SPLK) stock with a Neutral rating and a price target of $60.00
Splunk is a provider of software solutions. Its offerings enable users to collect, index, search, explore, monitor and analyze data. It operates through the development and marketing of software solutions segment, which enables its customers to gain real-time operational intelligence by harnessing the value of their data.
Investment analysts at Stifel upgraded Puma Biotechnology, Inc. (NYSE:PBYI) shares from a Hold to a Buy rating and raised their price objective from $61.00 to $88.00
Puma Biotechnology is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer